Company Filing History:
Years Active: 2018
Title: Innovations of Charles David Hartley
Introduction
Charles David Hartley is a notable inventor based in Essex, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors in the brain. His work is crucial for advancing treatments for diseases such as Alzheimer's.
Latest Patents
Hartley holds a patent for "Fused imidazole compounds." This invention provides compounds represented by a specific formula, including pharmaceutically acceptable salts, N-oxides, solvates, or prodrugs. The compounds exhibit affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAα5) and function as GABAα5 negative allosteric modulators (GABAα5 NAM). This innovation is particularly useful in the prevention and treatment of diseases related to GABAα5, including Alzheimer's disease. He has 1 patent to his name.
Career Highlights
Hartley is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to work on groundbreaking pharmaceutical innovations. His research focuses on developing new therapeutic options that can significantly impact patient care.
Collaborations
Some of his notable coworkers include Tetsuji Saito and Masato Higashino. Their collaborative efforts contribute to the advancement of research in the pharmaceutical field.
Conclusion
Charles David Hartley's work exemplifies the importance of innovation in medicine. His contributions to the development of GABAα5 modulators are paving the way for new treatments for Alzheimer's disease and other related conditions.